NASDAQ:INCYIncyte Stock Price, Forecast & News

Incyte's stock was trading at $71.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, INCY stock has increased by 42.8% and is now trading at $102.65. View which stocks have been most impacted by Coronavirus.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 10 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Incyte.

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Incyte.

Incyte Co. (NASDAQ:INCY) announced its quarterly earnings results on Tuesday, May, 5th. The biopharmaceutical company reported ($2.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.31 by $3.17. The biopharmaceutical company had revenue of $568.51 million for the quarter, compared to analyst estimates of $553.24 million. Incyte had a negative return on equity of 12.81% and a negative net margin of 16.87%. The business's revenue was up 14.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.62 earnings per share. View Incyte's earnings history.

23 analysts have issued 1-year price targets for Incyte's stock. Their forecasts range from $79.00 to $124.00. On average, they anticipate Incyte's share price to reach $100.65 in the next year. This suggests that the stock has a possible downside of 1.9%. View analysts' price targets for Incyte.

News coverage about INCY stock has trended very negative recently, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Incyte earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Incyte.

Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Immunomedics (IMMU) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Micron Technology (MU), Array Biopharma (ARRY) and Celgene (CELG).

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INCY stock can currently be purchased for approximately $102.65.

Incyte has a market capitalization of $22.31 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis. Incyte employs 1,456 workers across the globe.

The official website for Incyte is www.incyte.com.

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]